Interparfums

IPAR · NASDAQ

$115.90+$1.15 (+1.00%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $114.75

IPAR analyst rating

BuyConsensus of 6 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy3
Hold3
Underperform0
Sell0

12-month price target · 9 analysts

Average $127.27 (+9.8% upside)

Low: $85.85
Now: $115.90
High: $158.55

Upgrades and downgrades

The latest rating actions, newest first

IPAR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BWS Financial	Aug 17, 2026	Maintains	Neutral	$85.00	56%
TD Cowen	Aug 10, 2026	Downgrade	Buy → Hold	$110.00 → $120.00	61%
Goldman Sachs	Aug 10, 2026	Downgrade	Buy → Neutral	$110.00 → $129.00	—
Canaccord Genuity	Jul 30, 2026	Maintains	Buy	$141.00 → $151.00	42%
Jefferies	Jul 28, 2026	Maintains	Buy	$115.00 → $145.00	38%
Canaccord Genuity	Jul 23, 2026	Maintains	Buy	$123.00 → $141.00	42%
TD Cowen	Jun 1, 2026	Initiates	Buy	$110.00	61%
BWS Financial	Apr 22, 2026	Maintains	Neutral	$85.00	56%
BWS Financial	Jan 29, 2026	Maintains	Neutral	$85.00	56%
Jefferies	Jan 14, 2026	Initiates	Buy	$112.00	38%

The case for and against

Updated Oct 14, 2026

Bull case

Interparfums is supported by sustained sales momentum, with two quarters of growth and U.S. operations up 18% reported and 17% organic in 2Q, aided by stronger innovation, supply-chain recovery, and robust performance from GUESS, Donna Karan/DKNY, and other U.S.-managed brands. The firm’s upcoming innovation cycle, including Longchamp, Off-White, and new introductions across Montblanc, Coach, Guess, and Jimmy Choo, should reinforce growth through halo effects, although it requires elevated marketing spend and performance may vary by launch. The outlook remains constructive because the valuation re-rated from about 10x FY2 EV/EBITDA in June to 13.4x, reflecting confidence in execution while leaving upside if adoption of future fragrance launches or broader market growth exceeds expectations.

Bear case

Interparfums is facing a more cautious setup because much of the expected FY27 launch-driven upside appears already embedded after a roughly 30% rally since June, leaving limited near-term catalyst visibility. While 2Q26 sales of $341mm beat estimates, operating margin missed at $49mm and EPS came in at $0.95 as gross margin fell about 65bps from higher tariff costs, an unfavorable mix, and rising SG&A that increased 8% y/y. Weakness in Europe and the Middle East, which represent about 34% and 8% of sales, respectively, plus muted consumer demand through 2H26 and higher A&P spending, support a negative view on near-term earnings durability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.